U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C11H14N2S
Molecular Weight 206.307
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of PYRANTEL

SMILES

CN1CCCN=C1\C=C\C2=CC=CS2

InChI

InChIKey=YSAUAVHXTIETRK-AATRIKPKSA-N
InChI=1S/C11H14N2S/c1-13-8-3-7-12-11(13)6-5-10-4-2-9-14-10/h2,4-6,9H,3,7-8H2,1H3/b6-5+

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/monograph/pyrantel-pamoate.html

Pyrantel is an anthelmintic, which acts as an agonist of nicotinic receptors (AChRs) of nematodes and exerts its therapeutic effects by depolarizing their muscle membranes. It is used to treat a number of parasitic worm infections. This includes ascariasis, hookworm infections, enterobiasis (pinworm infection), trichostrongyliasis and trichinellosis. Common adverse reactions include diarrhea, nausea, vomiting, dizziness, headache and somnolence.

Originator

Approval Year

1971
86
Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Nicotinic receptors (AChRs) of nematodes
Agonist
2662
Target ID: Mouse α2βεδ AChRs
Agonist
2662
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8360
Strongid

Approved Use

Drug is indicated for the removal and control of mature infections of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); and large roundworms (Parascaris equorum) in horses and ponies.

Launch Date

6.4031038E11
Curative
Approved
8360
Strongid

Approved Use

Drug is indicated for the removal and control of mature infections of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); and large roundworms (Parascaris equorum) in horses and ponies.

Launch Date

6.4031038E11
Curative
Approved
8360
Strongid

Approved Use

Drug is indicated for the removal and control of mature infections of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); and large roundworms (Parascaris equorum) in horses and ponies.

Launch Date

6.4031038E11
Curative
Approved
8360
Strongid

Approved Use

Pyrantel pamoate is indicated for the removal and control of mature infections of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); large roundworms (Parascaris equorum) and tapeworms (Anoplocephala perfoliata) in horses and ponies.

Launch Date

6.4031038E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.09 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/11348490/
13.3 mg/kg single, oral
dose: 13.3 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
PYRANTEL plasma
Equus caballus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.06 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/11348490/
13.3 mg/kg single, oral
dose: 13.3 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
PYRANTEL plasma
Equus caballus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.43 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/11348490/
13.3 mg/kg single, oral
dose: 13.3 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
PYRANTEL plasma
Equus caballus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1709
substrate
1010
substrate
1193

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A1
348

CYP2C8
688

CYP1A2
1032

CYP2A6
523

CYP1B1
92

CYP2B6
660

CYP2C19
985

CYP2E1
648

CYP3A5
391

CYP4A11
102
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1032
 no
CYP1B1
92
 no
CYP2A6
523
 no
CYP2B6
660
 no
CYP2C19
985
 no
CYP2E1
648
 no
CYP3A4
1709
 no
CYP3A5
391
 no
CYP4A11
102
 no
CYP1A1
348
 yes
CYP2C8
688
 yes
CYP2C9
1010
 yes
CYP2D6
1193
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:8654
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8654
MolPort
MolPort-002-707-681
https://www.molport.com/shop/molecule-link/MolPort-002-707-681
ZINC
ZINC000000097996
http://zinc15.docking.org/substances/ZINC000000097996
PubMed

PubMed

TitleDatePubMed
Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s.
2001 Jan
Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.
2003 Sep
Patents

Patents

CN104292242A
3
US5036069
3
US7001889
3

Sample Use Guides

In Vitro Use Guide
A modified methyl-thiazolyltetrazolium (MTT) reduction assay revealed good in vitro anthelmintic efficacies against Haemonchus contortus infective larvae for pyrantel tartrate at effective dose 0.1 ug/ul – 0.9 ug/ul.
Name Type Language
PYRANTEL
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
pyrantel [INN]
Common Name English
PYRIMIDINE, 1,4,5,6-TETRAHYDRO-1-METHYL-2-(2-(2-THIENYL)ETHENYL)-
Systematic Name English
PYRANTEL [HSDB]
Common Name English
PYRANTEL [VANDF]
Common Name English
Pyrantel [WHO-DD]
Common Name English
PYRANTEL [MI]
Common Name English
KONVERMEX
Brand Name English
Classification Tree Code System Code
CFR 21 CFR 520.1871
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
WHO-VATC QP52AF02
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
CFR 21 CFR 520.1196
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.1.1
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
LIVERTOX NBK548238
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
WHO-ATC P02CC01
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
NCI_THESAURUS C250
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
CFR 21 CFR 520.1199
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
CFR 21 CFR 558.485
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
Code System Code Type Description
ECHA (EC/EINECS)
239-774-1
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
DAILYMED
4QIH0N49E7
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
EPA CompTox
DTXSID5023538
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
LACTMED
Pyrantel
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
ChEMBL
CHEMBL1626223
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
INN
2228
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
NCI_THESAURUS
C75231
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
WIKIPEDIA
PYRANTEL
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
CHEBI
8654
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
MERCK INDEX
M9336
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY Merck Index
SMS_ID
100000080865
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
DRUG CENTRAL
2999
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
HSDB
3252
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
MESH
D011715
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
DRUG BANK
DB11156
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
CAS
15686-83-6
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
FDA UNII
4QIH0N49E7
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
RXCUI
8984
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY RxNorm
PUBCHEM
708857
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
EVMPD
SUB10162MIG
Created by admin on Thu Jul 06 22:12:51 UTC 2023 , Edited by admin on Thu Jul 06 22:12:51 UTC 2023
PRIMARY
ACTIVE MOIETY
Structure of PYRANTEL
SALT/SOLVATE (PARENT)
Structure of PYRANTEL CITRATE
SALT/SOLVATE (PARENT)
Structure of PYRANTEL PAMOATE
SALT/SOLVATE (PARENT)
Structure of PYRANTEL TARTRATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966